Cargando…

Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction

Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hintschich, Constantin A., Dietz, Melanie, Haehner, Antje, Hummel, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605508/
https://www.ncbi.nlm.nih.gov/pubmed/36294918
http://dx.doi.org/10.3390/life12101483
_version_ 1784818084713857024
author Hintschich, Constantin A.
Dietz, Melanie
Haehner, Antje
Hummel, Thomas
author_facet Hintschich, Constantin A.
Dietz, Melanie
Haehner, Antje
Hummel, Thomas
author_sort Hintschich, Constantin A.
collection PubMed
description Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysically assessed the effect of intranasally applied mometasone furoate on the recovery of olfaction. The spray was applied with a long applicator so that the olfactory cleft could be reached effectively. After olfactory dysfunction had been confirmed psychophysically using Sniffin’ Sticks, patients were randomly assigned to two different treatment arms: the study group (n = 40) underwent olfactory training and intranasal administration of mometasone furoate twice daily, whereas the control group (n = 46) performed olfactory training only. After a study duration of three months, psychophysical testing of olfaction was repeated using Sniffin’ Sticks. We found no benefit of an additional topical administration of mometasone furoate compared to olfactory training alone. These results psychophysically confirm two previous studies which were based on patients’ subjective self-ratings. Our findings are in contrast to current recommendations for the management of olfactory dysfunction post-COVID-19, which might have to be adapted accordingly.
format Online
Article
Text
id pubmed-9605508
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96055082022-10-27 Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction Hintschich, Constantin A. Dietz, Melanie Haehner, Antje Hummel, Thomas Life (Basel) Article Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysically assessed the effect of intranasally applied mometasone furoate on the recovery of olfaction. The spray was applied with a long applicator so that the olfactory cleft could be reached effectively. After olfactory dysfunction had been confirmed psychophysically using Sniffin’ Sticks, patients were randomly assigned to two different treatment arms: the study group (n = 40) underwent olfactory training and intranasal administration of mometasone furoate twice daily, whereas the control group (n = 46) performed olfactory training only. After a study duration of three months, psychophysical testing of olfaction was repeated using Sniffin’ Sticks. We found no benefit of an additional topical administration of mometasone furoate compared to olfactory training alone. These results psychophysically confirm two previous studies which were based on patients’ subjective self-ratings. Our findings are in contrast to current recommendations for the management of olfactory dysfunction post-COVID-19, which might have to be adapted accordingly. MDPI 2022-09-24 /pmc/articles/PMC9605508/ /pubmed/36294918 http://dx.doi.org/10.3390/life12101483 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hintschich, Constantin A.
Dietz, Melanie
Haehner, Antje
Hummel, Thomas
Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
title Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
title_full Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
title_fullStr Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
title_full_unstemmed Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
title_short Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
title_sort topical administration of mometasone is not helpful in post-covid-19 olfactory dysfunction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605508/
https://www.ncbi.nlm.nih.gov/pubmed/36294918
http://dx.doi.org/10.3390/life12101483
work_keys_str_mv AT hintschichconstantina topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction
AT dietzmelanie topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction
AT haehnerantje topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction
AT hummelthomas topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction